2023-04-27 09:44:03 ET
- The U.S. Food and Drug Administration (FDA) accepted for review Takeda's resubmitted application seeking approval for subcutaneous (SC) administration of Entyvio as a maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous.
- Takeda said the refiling was aimed to address FDA feedback in a December 2019 Complete Response Letter (CRL).
- The Japanese drugmaker expects a decision from the FDA by the end of 2023.
For further details see:
Takeda's refiling for subcutaneous Entyvio gets FDA review